Second generation 18F-labeled prostate-specific membrane antigen targeted imaging agent found to be highly sensitive in detecting prostate cancer


A first-in-human prostate cancer study published in the Journal of Molecular Imaging and Biology showed initial safety, biodistribution, and dosimetry results with [18F]DCFPyL, a 2nd generation fluorine-18 labeled small-molecule PSMA inhibitor. The imaging biomarker has been developed at Johns Hopkins University in Baltimore, MD by study co-author, Martin G. Pomper, MD, PhD.